2021-01-12," <Research Report>M Stanley's Latest Ratings, TPs on CN Drugmakers (Table)  "
2020-12-28,   《HKEx》- 02616 CSTONE PHARMA-B - MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2020 
2020-12-15, CN Medical Insurance Drug Catalog Tweaked; 14 Exclusive Drugs' Avg Price Cut by Over 43% 
2020-12-15, *CICC: Mkt Bearish on Medical Insurance Innovative Drug Talks; Eyes Industry Policy Changes 
2020-12-15, *Macquarie Sees 60-80% Price Cut in Latest CN NRDL; Advises Bottom-fishing Drugmakers after Talks Over 
2020-11-11, CN's NRDL Drugs Subject to 50%- Price Cuts For Now: Rumours 
2020-11-11,   《HKEx》- 02616 CSTONE PHARMA-B - VOLUNTARY ANNOUNCEMENT - CSTONE''S PARTNER BLUEPRINT MEDICINES ANNOUNCED U.S. FDA HAS APPROVED GAVRETO (PRALSETINIB) FOR THE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC RET-MUTANT AND RET FUSION-POSITIVE THYROID CANCERS 
